| Ytd | 6.23% | |
| 1y | 15.82% |
| Open | 7.99 | Prev Close | 7.99 | Low | 7.97 | High | 8.35 | Mkt Cap | 1.44B |
| Vol | 904.70K | Avg Vol | 1.85M | EPS | -0.11 | P/E | -78.36 | Forward P/E | 20.33 |
| Beta | 0.66 | Short Ratio | 4.30 | Inst. Own | 61.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 7.66 | 200-d Avg | 7.05 | 1yr Est | 11.29 |
Xeris Biopharma NASDAQ: XERS reported second-quarter total revenue of $92.1 million, up 29% from a y
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the q
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The lates
Please replace the release issued earlier today with the following corrected version that provides a
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the f
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-grow
CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdin
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu
Xeris Biopharma has delivered another year of significant revenue growth, signaling a pivotal moment
Xeris Biopharma NASDAQ: XERS reported a sharp increase in first-quarter 2026 revenue and raised the
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the q
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS.
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has earned an average rating of "Mod
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn
Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 12
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for i
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earn
Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report q
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report
Monday morning saw 558 companies set new 52-week highs.
Gainers Inari Medical, Inc. (NASDAQ: NARI) shares surged 123.7% to close at $42.51 on Friday afte
Gainers Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) shares jumped 98.40% to $2.5201 after the
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Friday
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Friday
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Tuesday
Stocks Which Set New 52-Week High Yesterday, September 12
Stocks Which Set New 52-Week High Yesterday, September 11th
58 Biggest Movers From Yesterday